IDIQ contract for centralized chemopreventive agent repository and chemistry support services

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N91023D00010
Awardee
Awarding agency
Task orders
5 $29,710,575 obligated

Award facts

Opportunity
Combined order value
  • $29,710,575 Current, with exercised options
  • $35,387,133 Potential, with all options
Last date to order 66% complete
IDV ceiling 59% used
$49,990,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Cancer Institute awarded a single-award indefinite-delivery contract to Mriglobal (doing business as Midwest Research Institute) on July 1, 2023, with a ceiling of $49.99 million for centralized chemopreventive agent repository and chemistry support services. The IDIQ is structured with a five-year base period plus one-year option periods, with ultimate completion on June 30, 2028.

Work is performed in Kansas City, Missouri. The originating solicitation, posted January 13, 2023, sought logistical support for acquisition, storage, quality control, and distribution of investigational agents for cancer prevention studies. NAICS code 541690 applies; the small business size standard is $16.5 million.

Mriglobal is a 501(c)(3) nonprofit research organization based in Kansas City. The vendor is a large, unrestricted prime contractor with no small business set-aside designation.

Recent delivery orders under this IDIQ include a $26.9 million task order issued July 1, 2023, for centralized chemopreventive agent repository and chemistry support (cost-plus-fixed-fee, Kansas City, ultimate completion June 30, 2028); a $1.87 million order issued September 18, 2024, for production of drug substance, conversion to drug product, filling into applicators for clinical trials, and placebo production (cost-no-fee, Kansas City, completion September 17, 2026, with List Biological Laboratories named as subcontractor); a $2.79 million order issued September 25, 2024, for plasmid DNA drug substance and drug product manufacture (cost-no-fee, Rockville, Maryland, completion April 30, 2028); and a $3.46 million order issued September 22, 2025, for manufacture of clinical-grade Epstein-Barr virus vaccine (firm-fixed-price, Kansas City, completion September 21, 2027).

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00003 · EO 14398 IDIQ contract for centralized chemopreventive agent repository and chemistry support services $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $0

Subawards

Subcontractor Amount Awarded
The University Of Iowa CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT manufacturing of Tamoxifen $523,364
Lonza Walkersville, Inc. CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT Drug formulation $154,550
HDT Bio Corp MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE Technology Transfer, Analytical Methods, Production, Testing, and Master Cell Bank. $2,922,394
The University Of Iowa IDIQ CONTRACT FOR CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT SERVICES Procurement of pharmaceutical supplies. $150,648
Mckesson Corporation IDIQ CONTRACT FOR CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT SERVICES Procurement of pharmaceutical supplies. $66,199
Probio Inc. IDIQ CONTRACT FOR CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT SERVICES Cell banking $82,000
Brazos Relocation Services Inc. IDIQ CONTRACT FOR CENTRALIZED CHEMOPREVENTIVE AGENT REPOSITORY AND CHEMISTRY SUPPORT SERVICES Transport Cryoguys $52,692
Probio Inc. MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT Production of a primary cell bank, production of plasmid DNA drug substance. $1,343,550
List Biological Laboratories, Inc. THE SCOPE OF THIS TASK ORDER IS (1). PRODUCTION OF A DRUG SUBSTANCE, (2) CONVERSION OF DRUG SUBSTANCE TO DRUG PRODUCT, (3) FILLING DRUG PRODUCT INTO APPLICATORS… $1,624,701

Quick answers

Who was awarded contract 75N91023D00010?

75N91023D00010 was awarded to Mriglobal by National Cancer Institute (National Institutes of Health) on July 1, 2023.

How much is contract 75N91023D00010 worth?

Orders under 75N91023D00010 have obligated $29,710,575. Their combined potential value, with all options, is $35,387,133. 75N91023D00010's own ceiling is $49,990,000.

How many orders have been placed under contract 75N91023D00010?

5 orders have been placed under 75N91023D00010, the latest on September 21, 2026.

Who can order from contract 75N91023D00010?

75N91023D00010 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N91023D00010 competed?

The extent of competition for 75N91023D00010 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV